Dyslipidemia

Professor of medicine at Harvard Medical School discusses how much progress has been made in the fight against cardiovascular disease.

Over time, clinicians have come to understand the most optimal use of the limited technological resources they have.

How the institution has become involved in regional health education efforts, and national efforts to establish proper care protocol.

Why limited educational resources and a diverse population has made the region an area burdened by heart disease.

Recent analysis of 3 trials found that CERT2 showed comparable and synergistic predictive performance when compared with previously published CVD risk models.

A 6-month study examining the effects of hepatic-directed prandial insulin in patients with type 1 diabetes mellitus was presented at ADA 2019.

A new study shows patients with T1D and comorbid cardiovascular disease face a signficantly greater cost of care.

A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.

A decision for icosapent ethyl's sNDA is not expected to come from the FDA until September, but excitement surrounding the drug is at all-time high.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.

MAASTRICHT, The Netherlands--The significant combined effect of bempedoic acid and ezetimibe on LDL-C in patients at high risk for CV events may suggest a new era of non-statin therapy. 

MAASTRICHT, The Netherlands-Study results suggest that clinical trials of novel treatments targeting Lp(a) will not be affected by subjects with CV disease receiving antiplatelet therapy.

Data from ACC 2018 showed the PCSK9 inhibitor is associated with an absolute risk reduction of 1.6% in treated patients versus placebo.

About 4 million Americans can’t tolerate statins. A new study suggests bempedoic acid could be used to help these patients lower their LDL cholesterol.

In 2018, the American College of Cardiology and American Heart Association teamed up to update treatment guidelines for atherosclerotic cardiovascular disease. Learn more in this recap.

The application to the FDA for icosapent ethyl seeks a new indication to reduce the risk of major adverse cardiovascular events.

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

A new cohort assessment shows white and African American men both have a lifetime hypertension risk of more than 80%.

It's been 4 years since the drug class reached the market. Are patients adhering to the therapy, and what more potential does it have?

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

Atrial fibrillation patients at risk for acute coronary syndrome, stroke and blood clots have better outcomes with an antithrombotic regimen of apixaban without aspirin, researchers report.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

Physicians found bempedoic acid was capable of reducing LDL-C by another 18% without muscle or liver issues due to high-dose statin regimen.

Rodriguez discusses her team's recent 300,000-patient cohort analysis on statin adherence, plus advice on managing at-risk patients with ASCVD.